Growth Factor Receptor Fusions Predict Therapeutic Sensitivity
- PMID: 25995339
- DOI: 10.1158/1078-0432.CCR-15-0458
Growth Factor Receptor Fusions Predict Therapeutic Sensitivity
Abstract
Dysregulated growth factor pathways promote tumor growth in many cancers, but receptor-targeting strategies frequently offer limited benefit despite activation by receptor overexpression or amplification. In contrast, tumors harboring growth factor receptor fusions display exquisite dependence on receptor activity, providing predictive markers for patient response to inform precise oncology treatment.
©2015 American Association for Cancer Research.
Comment on
-
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.Clin Cancer Res. 2015 Jul 15;21(14):3307-17. doi: 10.1158/1078-0432.CCR-14-2199. Epub 2015 Jan 21. Clin Cancer Res. 2015. PMID: 25609060 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
